From infection to autoimmunity: A new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI)

Autoimmunity Reviews

Volumn 6, Issue 4, 2007, Pages 223-227

  Schultz, Hendrik ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adaptive immunity; Autoantibodies; Bactericidal permeability increasing protein; Endotoxin; Innate immunity

Indexed keywords

AUTOANTIBODY; BACTERIAL PROTEIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; ENDOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BACTERICIDAL ACTIVITY; CLINICAL FEATURE; CYSTIC FIBROSIS; DENDRITIC CELL; ENTERITIS; GRAM NEGATIVE BACTERIUM; HOST; HUMAN; IMMUNE RESPONSE; INFECTION; LONG TERM EXPOSURE; NEUTROPHIL GRANULE; NONHUMAN; REVIEW;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOIMMUNITY; BLOOD PROTEINS; ENDOTOXINS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MEMBRANE PROTEINS;

EID: 33847065361     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.08.005     Document Type: Review

References (37)

1. Alekshun M.N., and Levy S.B. Commensals upon us. Biochem Pharmacol 71 (2006) 893-900
2. Beutler B., and Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3 (2003) 169-176
3. Van Amersfoort E.S., Van Berkel T.J., and Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16 (2003) 379-414
4. Weiss J. Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP): structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 31 Pt 4 (2003) 785-790
5. Weiss J., Elsbach P., Olsson I., and Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphnuclear leukocytes. J Biol Chem 253 (1978) 2664-2672
6. Calafat J., Janssen H., Tool A., Dentener M.A., Knol E.F., Rosenberg H.F., et al. The bactericidal/permeability in creasing protein (BPI) is present in specific granules of human eosinophils. Blood 91 (1998) 4770-4775
7. Canny G., Levy O., Furuta G.T., Narravalu-Alipati S., Sisson R.B., Serhan C.N., et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A 99 (2002) 3902-3907
8. Reichel P.H., Seemann C., Csernok E., Schroder J.M., Muller A., Gross W.L., et al. Bactericidal/permeability-increasing protein is expressed by human dermal fibroblasts and upregulated by interleukin 4. Clin Diagn Lab Immunol 10 (2003) 473-475
9. Beamer L.J., Carroll S.F., and Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. Science 276 (1997) 1861-1864
10. Gazzano-Santoro H., Parent J.B., Grinna L., Horwitz A., Parsons T., Theofan G., et al. High-affinity binding of the bactericidal/permeability increasing protein and a recombinant amino-terminal fragment to the Lipid A region of lipopolysaccharide. Infect Immun 60 (1992) 4754-4761
11. Mannion B.A., Weiss J., and Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest 85 (1990) 853-860
12. Marra M.N., Wilde C.G., Griffith J.E., Snable J.L., and Scott R.W. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 144 (1990) 662-666
13. Iovine N.M., Elsbach P., and Weiss J. An opsonic function of the neutrophil bactericidal/permeability increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci U S A 94 (1997) 10973-10978
14. Iovine N., Eastvold J., Elsbach P., Weiss J.P., and Gioannini T.L. The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes. J Biol Chem 277 (2002) 7970-7978
15. Kohn F.R., Ammons W.S., Horwitz A., Grinna L., Theofan G., Weickmann J., et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/ permeability-increasing protein in experimental endotoxemia. J Infect Dis 168 (1993) 1307-1310
16. Gioannini T.L., Teghanemt A., Zhang D., Levis E.N., and Weiss J.P. Monomeric endotoxin:protein complexes are essential for TLR4-dependent cell activation. J Endotoxin Res 111 (2005) 117-123
17. Zhao M.H., Jones S.J., and Lockwood C.M. Bactericidal/permeability increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 99 (1995) 49-56
18. Zhao M.H., Jayne D.R., Ardiles L.G., Culley F., Hodson M.E., and Lockwood C.M. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 89 (1996) 259-265
19. Stoffel M.P., Csernok E., Herzberg C., Johnston T., Carroll S.F., and Gross W.L. Antineutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/ permeability increasing protein (BPI): A new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 104 (1996) 54-59
20. Schultz H., Schinke S., Weiss J., Cerundolo V., Gross W.L., and Gadola S. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections. Clin Exp Immunol 133 (2003) 252-259
21. Schultz H., Csernok E., Nikkari S., Toivanen P., Toivanen A., and Gross W.L. BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule. Scand J Rheumatol 29 (2000) 226-231
22. Mahadeva R., Dunn A.C., Westerbeek R.C., Sharples L., Whitehouse D.B., Carroll N.R., et al. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 117 (1999) 561-567
23. Schultz H., Schinke S., Mosler K., Herlyn K., Schuster A., and Gross W.L. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E.coli DH5α in vitro. Pediatr Pulmonol 37 (2004) 158-164
24. Schinke S., Fellermann K., Herlyn K., Reichel P.H., Fundke R., Stange E.F., et al. Autoantibodies against the bactericidal/permeability-increasing protein (BPI) from inflammatory bowel disease patients can impair the antibiotic activity of BPI. Inflamm Bowel Dis 10 (2004) 763-770
25. Folwaczny C., Jochum M., Noehl N., Schnettler D., Loeschke K., and Fricke H. p-ANCA target antigens in ulcerative colitis. Z Gastroenterol 36 (1998) 625-633
26. Charles L.A., Caldas M.L., Falk R.J., Terrell R.S., and Jennette J.C. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 50 (1991) 539-546
27. Schultz H., Csernok E., Schuster A., Schmitz T.S., Ernst M., and Gross W.L. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol 11 (2000) 64-70
28. Munford R.S. Detoxifying endotoxin: time, place and person. J Endotoxin Res 11 (2005) 69-84
29. Post D.M., Zhang D., Eastvold J.S., Teghanemt A., Gibson B.W., and Weiss J.P. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem 280 (2005) 38383-38394
30. Steinman R.M. Some interfaces of dendritic cell biology. APMIS 111 (2003) 6756-6797
31. Blander J.M., and Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440 (2006) 808-812
32. Lu M., Zhang M., Kitchens R.L., Fosmire S., Takashima A., and Munford R.S. Stimulus-dependent deacylation of bacterial lipopolysaccharide by dendritic cells. J Exp Med 197 (2003) 1745-1754
33. Munford R.S., and Hall C.L. Uptake and deacylation of bacterial lipopolysaccharides by macrophages from normal and endotoxin-hyporesponsive mice. Infect Immun 48 (1985) 464-473
34. Lu M., Zhang M., Takashima A., Weiss J., Apicella M.A., Li X.H., et al. Lipopolysaccharide deacylation by an endogenous lipase controls innate antibody responses to Gram-negative bacteria. Nat Immunol 6 (2005) 989-994
35. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
36. Schultz H., Heintz H., van Zandbergen G., Ullrich S., Reinhold-Keller E., and Gross W.L. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. Clin Exp Rheumatol 21 (2003) 763-766
37. Vermont C.L., van den Dobbelsteen G.P., and de Groot R. Recent developments in vaccines to prevent meningococcal serogroup B infections. Curr Opin Mol Ther 5 (2003) 33-38